Research Notes

HIV Hitches a Ride The statistics are grim: More than 34 million people worldwide affected with HIV/AIDS, and 800,000- 900,000 cases in the United States with a steady rate of 40,000 new HIV infections each year. Fueled by such statistics, HIV research continues with scientists at the National Institute of Allergy and Infectious Diseases (NIAID) recently discovering a mechanism providing insight into the pathogenesis of the virus in which HIV may hitch a ride from select cells to target cells.

Written byKate Devine
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The statistics are grim: More than 34 million people worldwide affected with HIV/AIDS, and 800,000- 900,000 cases in the United States with a steady rate of 40,000 new HIV infections each year. Fueled by such statistics, HIV research continues with scientists at the National Institute of Allergy and Infectious Diseases (NIAID) recently discovering a mechanism providing insight into the pathogenesis of the virus in which HIV may hitch a ride from select cells to target cells. Researchers report that B cells, the antibody-producing cells of the immune system, can likely deliver HIV to immune system T cells, those essential for a vigorous immune response (S. Moir et al., "B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells," Journal of Experimental Medicine, 192:637-45, Sept. 5, 2000). HIV devastates the body's ability to fight off infection by destroying a key class of these ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies